Glen A Lutchman, MD. Clinical Associate Professor, Medicine - Gastroenterology & Hepatology. Bio

Similar documents
Gabriel Garcia, MD. Bio

Mindie H. Nguyen, MD, MAS, AGAF, FAASLD

Mindie H. Nguyen, MD, MAS, AGAF, FAASLD

Mindie H. Nguyen, MD, MAS, AGAF, FAASLD

Intron A Hepatitis B. Intron A (interferon alfa-2b) Description

Aijaz Ahmed, MD. Bio. MC 5309 Stanford, CA Tel (650) Fax (650) BIO CLINICAL FOCUS ACADEMIC APPOINTMENTS

Hepatocellular Carcinoma: Can We Slow the Rising Incidence?

Harvoni: solution to HCV

Caution: Reactivation of Hepatitis B during Hepatitis C Treatment with Direct-Acting Antiviral Therapy

Mavyret (glecaprevir/pibrentasvir)

Hepatitis C Resistance Associated Variants (RAVs)

29th Viral Hepatitis Prevention Board Meeting

Management of Chronic Hepatitis B in Asian Americans

Chronic Hepatitis B: management update.

Sovaldi (sofosbuvir) with Pegasys (peginterferon alfa-2a) and Ribavirin (Copegus, Moderiba, Rebetol, RibaPak, Ribasphere, RibaTab, ribavirin)

An Update HBV Treatment

Hepatitis B Reactivation

Hepatitis C Virus Clinical Criteria Update September 18, For: New York State Medicaid

The Impact of HBV Therapy on Fibrosis and Cirrhosis

Treatment Options in HCV Relapsers and Nonresponders. Raymond T. Chung, M.D.

The following page contains the final YODA Project review approving this proposal.

See Important Reminder at the end of this policy for important regulatory and legal information.

Sovaldi (sofosbuvir) with PegIntron (peginterferon alfa-2b) and Ribavirin (Copegus, Moderiba, Rebetol, RibaPak, Ribasphere, RibaTab, ribavirin)

Viral Hepatitis The Preventive Potential of Antiviral Therapy. Thomas Berg

Update on Real-World Experience With HARVONI

MedInform. HBV DNA loss in Bulgarian patients on NUC therapy. Speed related factors. (NUC related speed of HBV DNA loss in Bulgaria) Original Article

Pegylated Interferon Agents for Hepatitis C

Dr David Rowbotham NHS. The Leeds Teaching Hospitals. NHS Trust

2017 UnitedHealthcare Services, Inc.

Clinical Policy: Glecaprevir/Pibrentasvir (Mavyret) Reference Number: CP.PHAR.348 Effective Date: 09/17

Hepatitis B Virus. Taylor Page PharmD Candidate 2019 February 1, 2019

Topic: Sovaldi, sofosbuvir Date of Origin: March 14, Committee Approval Date: August 15, 2014 Next Review Date: March 2015

MANAGEMENT OF HBV & HCV INFECTION---SIMILARITIES & DISSIMILARITIES---PAST AND PRESENT. Professor Salimur Rahman

New York State HCV Provider Webinar Series. Side Effects of Therapy

Hepatitis B Treatment Pearls. Agenda

Hepatitis C No Barriers to Cure

Monitoring Patients Who Are Starting HCV Treatment, Are On Treatment, Or Have Completed Therapy

Original article Ledipasvir and sofosbuvir for HCV infection in patients coinfected with HBV

5/12/2016. Learning Objectives. Management of Hepatitis C Virus Genotype 2 or 3 Infected Treatment-Naive or Experienced Patients

2/12/2018. David M. Fettig, M.D. Birmingham Gastroenterology Associates. Outline basics of Hepatitis B. Phases of Chronic Hepatitis B

Pegasys Ribavirin

Mavyret (glecaprevir/pibrentasvir)

Outline. Updates in the Clinical Management of Hepatitis B and C. Who should be screened for HBV? Chronic Hepatitis B 10/7/2018

Pegylated Interferons and Ribavirins

Antiviral agents in HCV

Primary Care for Hepatitis B and C:

Olysio Pegasys Ribavirin

See Important Reminder at the end of this policy for important regulatory and legal information.

29th Viral Hepatitis Prevention Board Meeting

2018 UnitedHealthcare Services, Inc.

See Important Reminder at the end of this policy for important regulatory and legal information.

Management of HBV in KidneyTransplanted Patients Dr.E.Nemati

Hepatitis B Diagnosis and Management. Marion Peters University of California San Francisco

Management of chronic hepatitis B : recent advance in the treatment of antiviral resistance

Viral Hepatitis And Liver Transplantation

Horizon Scanning Centre November Faldaprevir with BI for chronic hepatitis C infection, genotype 1 SUMMARY NIHR HSC ID: 7688

Intron A HEPATITIS B. Intron A (interferon alfa-2b) Description

Clinical Policy: Sofosbuvir/Velpatasvir/Voxilaprevir (Vosevi) Reference Number: GA.PMN.25 Product: Medicaid Effective Date: 9/17

Consensus AASLD-EASL HBV Treatment Endpoint and HBV Cure Definition

Current Status of HBV and Liver Transplant

Our better understanding of the natural

Scottish Medicines Consortium

Update in the Management of Hepatitis C: What Does the Future Hold

It is the policy of health plans affiliated with Centene Corporation that Mavyret is medically necessary when the following criteria are met:

Clinical Criteria for Hepatitis C (HCV) Therapy

Safety of Treatment in Cirrhotics in the Era of New Antiviral Therapies for Hepatitis C Virus

Seyed Moayed Alavian Professor of Gastroenterology and Hepatology Editor in-chief of Hepatitis Monthly E mail:

Associate Professor of Medicine University of Chicago

Cornerstones of Hepatitis B: Past, Present and Future

See Important Reminder at the end of this policy for important regulatory and legal information.

The natural course of chronic HBV infection can be divided into four, which are not always continuous.

Cost effectiveness of sofosbuvir and ledipasvir (Harvoni ) in combination with other medicinal products for the treatment of hepatitis C infection

Serum Hepatitis B Surface Antigen Levels Help Predict Disease Progression in Patients With Low Hepatitis B Virus Loads. Hepatology Feb 2013

COMPARISON OF HCV TREATMENT; HCV MONO-INFECTED AND HCV/HBV CO-INFECTED PATIENTS.

Clinical Policy: Glecaprevir/Pibrentasvir (Mavyret) Reference Number: GA.PMN.24 Product: Medicaid Effective Date: 9/17

Hepatitis C Management and Treatment

Dynamics of HBV DNA Levels, HBV Mutations and Biochemical Parameters during Antiviral Therapy in a Patient with HBeAg-Negative Chronic Hepatitis B

Long-term Clinical Outcomes and Risk of Hepatocellular Carcinoma in Chronic Hepatitis B Patients with HBsAg Seroclearance

Hepatitis B. Epidemiology and Natural History and Implications for Treatment

Autoimmune Hepatitis Events Easl

entecavir, 0.5mg and 1mg film-coated tablets and 0.05 mg/ml oral solution, Baraclude SMC No. (747/11) Bristol-Myers Squibb Pharmaceuticals Ltd

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Viral Hepatitis. Dr Melissa Haines Gastroenterologist Waikato Hospital

PEGINTRON (peginterferon alfa-2b) SECTION 1: Pegintron - Hepatitis C Monotherapy

SUMMACARE COMMERCIAL MEDICATION REQUEST GUIDELINES

HARVARD PILGRIM HEALTH CARE RECOMMENDED MEDICATION REQUEST GUIDELINES

10/21/2016. Susanna Naggie, MD, MHS Associate Professor of Medicine Duke University Durham, North Carolina. Learning Objectives

Pegasys Pegintron Ribavirin

SECTION 1: OLYSIO with (PEGASYS) AND RIBAVIRIN SECTION 2: OLYSIO with (PEGINTRON) AND RIBAVIRIN RATIONALE FOR INCLUSION IN PA PROGRAM

SVR Updates from the 2013 EASL

Screening for HCCwho,

BVHG/BASL/BSG/BHIVA/BIA/CVN Guidelines for management of chronic HCV infection

Impatto della clearance virale e rischio di carcinoma epatocellulare

Conventional Interferon Alfa-2b and Ribavirin for 12 Versus 24 Weeks in HCV Genotype 2 or 3

Infergen (interferon alfacon-1) with Ribavirin (Copegus, Rebetol, RibaPak, Ribasphere, RibaTab, ribavirin tablets/capsules - all strengths)

Special Contribution Highlights of the 2012 American Association for the Study of Liver Diseases Meeting

Ari Bunim, M.D. Director of Hepatology New York Hospital Queens Assistant Professor of Clinical Medicine Weill Cornell Medical College

CURRENT TREATMENT. Mitchell L Shiffman, MD Director Liver Institute of Virginia Bon Secours Health System Richmond and Newport News, Virginia

Transcription:

Clinical Associate Professor, Medicine - Gastroenterology & Hepatology Curriculum Vitae available Online CLINICAL OFFICES Stanford Gastroenterology and Digestive Health Clinic 450 Broadway St Bio Pav D 2nd Fl Pod 2 and 3 Redwood City, CA 94063 Tel (650) 498-7999 Fax (650) 724-9454 CLINICAL FOCUS Liver Transplantation Gastroenterology ACADEMIC APPOINTMENTS Clinical Associate Professor, Medicine - Gastroenterology & Hepatology HONORS AND AWARDS Honors in Biochemistry, University of the West Indies (1996) Honors in Pharmacology, University of the West Indies (1996) Honors in Obstetrics and Gynecology, University of the West Indies (1996) Chin Yee Prize for Surgery, University of the West Indies (1996) NIH Intramural Fellows Travel Award, National Institutes of Health (2003) AASLD Advanced Hepatology Fellowship,, American Association for the Study of Liver Diseases (2007-2008) PROFESSIONAL EDUCATION Board Certification: Internal Medicine, American Board of Internal Medicine (2001) Fellowship: UCSF Div of Gastroenterology (2008) CA Fellowship: UCSF Div of Gastroenterology (2007) CA Residency: SUNY at Brooklyn School Of Medicine (2002) NY Board Certification: Transplant Hepatology, American Board of Internal Medicine (2008) Board Certification: Gastroenterology, American Board of Internal Medicine (2007) Board Certification, American Board of Internal Medicine, Transplant Hepatology (2008) Fellowship: National Institutes of Health (2005) MD Page 1 of 5

Medical Education: University of the West Indies (1996) West Indies Fellow, UCSF Medical Center, Transplant Hepatology (2008) Research Fellow, National Institutes of Health, Hepatology Research (2005) MHSc, Duke University, Clinical Research (2005) Chief Resident, SUNY Downstate Medical Center, Internal Medicine (2002) Resident, SUNY Downstate Medical Center, Internal Medicine (2001) MBBS, University of the West Indies, Medicine (1996) Research & Scholarship CURRENT RESEARCH AND SCHOLARLY INTERESTS My primary research interest is in metabolic liver disease primarily non-alcoholic steatohepatitis. I also have an interest in transplant outcomes for patients with chronic hepatitis C. CLINICAL TRIALS Once-Daily Oral Avatrombopag Tablets Used in Subjects With Chronic Liver Diseases and Thrombocytopenia Prior to Elective Surgical or Diagnostic Procedures, Recruiting Teaching GRADUATE AND FELLOWSHIP PROGRAM AFFILIATIONS Medicine (Masters Program) Publications PUBLICATIONS OUTCOME OF EN-BLOC COMBINED HEART AND LIVER TRANSPLANTATION IN THE ADULT FAILING FONTAN Vaikunth, S., Concepcion, W., Daugherty, T., Fowler, M., Lutchman, G., Maeda, K., Rosenthal, D., Teuteberg, J., Woo, Y., Lui, G. K. ELSEVIER SCIENCE INC.2018: 539 Safety and Efficacy of Velpatasvir and Sofosbuvir-based Regimens for the Treatment of HCV Genotype 1-6: Results of the HCV-TARGET Study Landis, C. S., Sulkowski, M. S., Reau, N., Lutchman, G. A., Vainorius, M., Welzel, T. M., Zeuzem, S., Khalili, M., Nelson, D. R., Lok, A. S., Fried, M. W., Terrault, N., HCV-TAR-Get Network WILEY.2017: 587A Real-world experience with interferon-free, direct acting antiviral therapies in Asian Americans with chronic hepatitis C and advanced liver disease. Medicine Chang, C. Y., Nguyen, P., Le, A., Zhao, C., Ahmed, A., Daugherty, T., Garcia, G., Lutchman, G., Kumari, R., Nguyen, M. H. 2017; 96 (6) Effectiveness and tolerability of simeprevir and sofosbuvir in nontransplant and post-liver transplant patients with hepatitis C genotype 1. Alimentary pharmacology & therapeutics Lutchman, G., Nguyen, N. H., Chang, C. Y., Ahmed, A., Daugherty, T., Garcia, G., Kumari, R., Gupta, S., Doshi, D., Nguyen, M. H. 2016; 44 (7): 738-746 Lower response to simeprevir and sofosbuvir in HCV genotype 1 in routine practice compared with clinical trials. BMJ open gastroenterology Yee, B. E., Nguyen, N. H., Jin, M., Lutchman, G., Lim, J. K., Nguyen, M. H. 2016; 3 (1) Tolerability and effectiveness of sofosbuvir and simeprevir in the post-transplant setting: systematic review and meta-analysis. BMJ open gastroenterology Nguyen, N. H., Yee, B. E., Chang, C., Jin, M., Lutchman, G., Lim, J. K., Nguyen, M. H. 2016; 3 (1) Page 2 of 5

A glass half full: Implications of screening for hepatitis C virus in the era of highly effective antiviral therapy. Hepatology Lutchman, G., Kim, W. R. 2015; 61 (5): 1455-1458 Recurrent Hepatocellular Carcinoma and Poorer Overall Survival in Patients Undergoing Left-sided Compared With Right-sided Partial Hepatectomy. Journal of clinical gastroenterology Valenzuela, A., Ha, N. B., Gallo, A., Bonham, C., Ahmed, A., Melcher, M., Kim, L. H., Esquivel, C., Concepcion, W., Ayoub, W. S., Lutchman, G. A., Daugherty, T., Nguyen, et al 2015; 49 (2): 158-164 Safety and efficacy of entecavir in adefovir-experienced patients JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY Nguyen, N. H., Trinh, H. N., Nguyen, T. T., Do, S. T., Tran, P., Nguyen, H. A., Nguyen, K. K., Garcia, R. T., Lutchman, G. A., Nguyen, M. H. 2015; 30 (1): 43-50 Sustained virological response and its treatment predictors in hepatitis C virus genotype 4 compared to genotypes 1, 2, and 3: a meta-analysis. BMJ open gastroenterology Yee, B. E., Nguyen, N. H., Zhang, B., Lin, D., Vutien, P., Wong, C. R., Lutchman, G. A., Nguyen, M. H. 2015; 2 (1) Treatment of Acute Hepatitis C Infection with Pegylated Interferon and Ribavirin in Patients Coinfected with Human Immunodeficiency Virus: A Systematic Review and Meta-Analysis INTERVIROLOGY Zhang, B., Nguyen, N. H., Yee, B. E., Yip, B., Ayoub, W. S., Lutchman, G. A., Nguyen, M. H. 2015; 58 (4): 242-249 Meta-analysis: influence of host and viral factors in patients with chronic hepatitis C genotype 4 treated with pegylated interferon and ribavirin EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY Yee, B. E., Nguyen, N. H., Zhang, B., Vutien, P., Wong, C. R., Lutchman, G. A., Nguyen, M. H. 2014; 26 (11): 1189-1201 Meta-analysis: influence of host and viral factors in patients with chronic hepatitis C genotype 4 treated with pegylated interferon and ribavirin. European journal of gastroenterology & hepatology Yee, B. E., Nguyen, N. H., Zhang, B., Vutien, P., Wong, C. R., Lutchman, G. A., Nguyen, M. H. 2014; 26 (11): 1189-1201 Mutations in HBV DNA polymerase associated with nucleos(t)ide resistance are rare in treatment-naive patients. Clinical gastroenterology and hepatology Vutien, P., Trinh, H. N., Garcia, R. T., Nguyen, H. A., Levitt, B. S., Nguyen, K., da Silveira, E., Daugherty, T., Ahmed, A., Garcia, G., Lutchman, G. A., Nguyen, M. H. 2014; 12 (8): 1363-1370 Mutations in HBV DNA Polymerase Associated With Nucleos(t)ide Resistance Are Rare in Treatment-naive Patients. Clinical gastroenterology and hepatology Vutien, P., Trinh, H. N., Garcia, R. T., Nguyen, H. A., Levitt, B. S., Nguyen, K., da Silveira, E., Daugherty, T., Ahmed, A., Garcia, G., Lutchman, G. A., Nguyen, M. H. 2014; 12 (8): 1363-1370 Primary surgical resection versus liver transplantation for transplant-eligible hepatocellular carcinoma patients. Digestive diseases and sciences Wong, R. J., Wantuck, J., Valenzuela, A., Ahmed, A., Bonham, C., Gallo, A., Melcher, M. L., Lutchman, G., Concepcion, W., Esquivel, C., Garcia, G., Daugherty, T., Nguyen, et al 2014; 59 (1): 183-191 Both HCV and HBV are Major Causes of Liver Cancer in Southeast Asians. Journal of immigrant and minority health Lin, H., Ha, N. B., Ahmed, A., Ayoub, W., Daugherty, T. J., Lutchman, G. A., Garcia, G., Nguyen, M. H. 2013; 15 (6): 1023-1029 Incidence of Hepatocellular Carcinoma Among US Patients With Cirrhosis of Viral or Nonviral Etiologies CLINICAL GASTROENTEROLOGY AND HEPATOLOGY Mair, R. D., Valenzuela, A., Ha, N. B., Ayoub, W. S., Daugherty, T., Lutchman, G. A., Garcia, G., Ahmed, A., Nguyen, M. H. 2012; 10 (12): 1412-1417 Risk factors for hepatocellular carcinoma in patients with chronic liver disease: a case-control study CANCER CAUSES & CONTROL Ha, N. B., Ha, N. B., Ahmed, A., Ayoub, W., Daugherty, T. J., Chang, E. T., Lutchman, G. A., Garcia, G., Cooper, A. D., Keeffe, E. B., Nguyen, M. H. Page 3 of 5

2012; 23 (3): 455-462 Ethnic Differences in Viral Dominance Patterns in Patients with Hepatitis B Virus and Hepatitis C Virus Dual Infection HEPATOLOGY Nguyen, L. H., Ko, S., Wong, S. S., Tran, P. S., Trinh, H. N., Garcia, R. T., Ahmed, A., Lutchman, G. A., Keeffe, E. B., Nguyen, M. H. 2011; 53 (6): 1839-1845 Screening for Hepatocellular Carcinoma After HBsAg Clearance Age Before Cirrhosis? JOURNAL OF CLINICAL GASTROENTEROLOGY Lutchman, G. A., Nguyen, M. A. 2011; 45 (1): 4-5 Endoscopic Management of a Spontaneous Gallbladder Perforation and Bile Leak DIGESTIVE DISEASES AND SCIENCES Munroe, C., Padilla-Thornton, A. E., Triadafilopoulos, G., Van Dam, J., Lutchman, G. 2010; 55 (10): 2767-2769 Ribavirin Improves Early Responses to Peginterferon Through Improved Interferon Signaling GASTROENTEROLOGY Feld, J. J., Lutchman, G. A., Heller, T., Hara, K., Pfeiffer, J. K., Leff, R. D., Meek, C., Rivera, M., Ko, M., Koh, C., Rotman, Y., Ghany, M. G., Haynes-Williams, et al 2010; 139 (1): 154-U239 Reactivation of Hepatitis B With Reappearance of Hepatitis B Surface Antigen After Chemotherapy and Immunosuppression CLINICAL GASTROENTEROLOGY AND HEPATOLOGY Palmore, T. N., Shah, N. L., Loomba, R., Borg, B. B., Lopatin, U., Feld, J. J., Khokhar, F., Lutchman, G., Kleiner, D. E., Young, N. S., Childs, R., Barrett, A. J., Liang, et al 2009; 7 (10): 1130-1137 Clinical trial: pilot study of metformin for the treatment of non-alcoholic steatohepatitis ALIMENTARY PHARMACOLOGY & THERAPEUTICS Loomba, R., Lutchman, G., Kleiner, D. E., Ricks, M., Feld, J. J., Borg, B. B., Modi, A., Nagabhyru, P., Sumner, A. E., Liang, T. J., Hoofnagle, J. H. 2009; 29 (2): 172-182 The effects of discontinuing pioglitazone in patients with nonalcoholic steatohepatitis HEPATOLOGY Lutchman, G., Modi, A., Kleiner, D. E., Promrat, K., Heller, T., Ghany, M., Borg, B., Loomba, R., Liang, T. J., Premkumar, A., Hoofnagle, J. H. 2007; 46 (2): 424-429 Mutation rate of the hepatitis C virus NS5B in patients undergoing treatment with ribavirin monotherapy GASTROENTEROLOGY Lutchman, G., Danehower, S., Song, B., Liang, T. J., Hoofnagle, J. H., Thomson, M., Ghany, M. G. 2007; 132 (5): 1757-1766 Changes in serum adipokine levels during pioglitazone treatment for nonalcoholic steatohepatitis: Relationship to histological improvement CLINICAL GASTROENTEROLOGY AND HEPATOLOGY Lutchman, G., Promrat, K., Kleiner, D. E., Heller, T., Ghany, M. G., Yanovski, J. A., Liang, T. J., Hoofnagle, J. H. 2006; 4 (8): 1048-1052 Steatosis and progression of fibrosis in untreated patients with chronic hepatitis C infection HEPATOLOGY Perumalswami, P., Kleiner, D. E., Lutchman, G., Heller, T., Borg, B., Park, Y., Liang, T. J., Hoofnagle, J. H., Ghany, M. G. 2006; 43 (4): 780-787 Pilot study of interferon gamma for chronic hepatitis C JOURNAL OF HEPATOLOGY Soza, A., Heller, T., Ghany, M., Lutchman, G., Liang, T. J., Germain, J., Hsu, H. H., Park, Y., Hoofnagle, J. H. 2005; 43 (1): 67-71 Pushing the treatment envelope for chronic hepatitis C - Is more necessarily better? HEPATOLOGY Lutchman, G., Ghany, M. 2005; 41 (2): 234-236 A pilot study of ploglitazone treatment for nonalcoholic steatohepatitis HEPATOLOGY Promrat, K., Lutchman, G., Uwaifo, G. I., Freedman, R. J., Soza, A., Heller, T., Doo, E., Ghany, M., Premkumar, A., Park, Y., Liang, T. J., Yanovski, J. A., Kleiner, et al 2004; 39 (1): 188-196 Viral kinetics in hepatitis C HEPATOLOGY Lutchman, G., Hoofnagle, J. H. Page 4 of 5

2003; 37 (6): 1257-1259 Page 5 of 5